Robbins LLP Asks Replimune Stockholders with Losses to Contact Firm
Robbins LLP is reminding Replimune Group, Inc. shareholders who have suffered significant losses to contact the firm before the October 5, 2026 lead plaintiff deadline.
The law firm Robbins LLP is initiating legal action concerning Replimune Group, Inc. (NASDAQ: REPL). Investors who purchased or acquired the company's securities between October 20, 2025, and April [date not specified] are being urged to contact the firm.
The case alleges that Replimune may have made misleading statements about its business and financial condition. The deadline for investors to be appointed lead plaintiff in the class action is October 5, 2026.
According to Robbins LLP, the company may have provided false or misleading information regarding the progression of its cancer treatments' clinical trials. The press release does not specify the exact nature of these alleged misstatements or which trials are involved.
Investors who have incurred substantial losses from their REPL stock purchases are encouraged to reach out to Robbins LLP for further information on their legal options prior to the deadline. The law firm offers free consultation.